The number of NK cells present, sufficient cytokine production, as well as expression of activating NK cell receptors with matching HLA-counterparts appear to be important prognostic features for molecular remission in CML. The gene discussed is KLRD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.